Effects of Hyulbuchuko-tang on blood flow in patients with cerebral infarction

Effects of Hyulbuchuko-tang on erythrocyte deformability and aggregation after stroke; PILOT Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0001748

Enrollment

Registered

2015-12-31

Start date

2011-12-01

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Water (150 mL) was administered orally in the first phase, and HBCt extract (6g) was administered orally in the second phase. The interval between the two phases was 24 hours. Blood sampling wa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: They had no major cognitive impairment (Korean version of the Mini-Mental State Examination [MMSE-K] score = 20). Even if patients had more than mild communication deficits and/or cognitive impairment (MMSE-K score < 20), they were included if their guardians agreed.

Exclusion criteria

Exclusion criteria: hematologic disease (blood coagulation defect, anemia, etc.) and fluid therapy or treatment with pentoxifylline, isoxsuprine, naphtidrofuryl, bencyclane, piracetam, ginkgo biloba extract, troxerutin, or rutosides, which could affect erythrocyte deformability.

Design outcomes

Primary

Measure	Time frame
Erythrocyte Defromability	—

Secondary

Measure	Time frame
Relationship between Erythrocyte Deformability and Blood Stasis Index	—

Countries

Korea, Republic of

Contacts

Public ContactJoonYoung Park

Kyung Hee University Oriental Medical Center

Outcome results